TRXADE HEALTH INC (MEDS) Forecast, Price Target & Analyst Ratings

NASDAQ:MEDS • US89846A4058

Current stock price

7.59 USD
+0.35 (+4.83%)
At close:
7.591 USD
+0 (+0.01%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TRXADE HEALTH INC (MEDS).

Forecast Snapshot

Consensus Price Target

Price Target
$6.89
-9.29% Downside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q3 / 2024
EPS Estimate
-$0.15
Revenue Estimate
2.525M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$6.89
Upside
-9.29%
From current price of $7.59 to mean target of $6.89, Based on 7 analyst forecasts
Low
$6.82
Median
$6.89
High
$7.09

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for MEDS. The average price target is 6.89 USD. This implies a price decrease of -9.29% is expected in the next year compared to the current price of 7.59.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

MEDS Current Analyst RatingMEDS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

MEDS Historical Analyst RatingsMEDS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
MEDS was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about MEDS.
In the previous month the buy percentage consensus was at a similar level.
MEDS was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-05-16EF HuttonMaintains Buy -> Buy
2023-03-28Maxim GroupMaintains Buy
2021-12-09EF HuttonInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q3 / 2024
EPS Estimate
-$0.15
Revenue Estimate
2.525M
Revenue Q2Q
22.69%
EPS Q2Q
0.00%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2024

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024
Revenue
YoY % growth
MEDS revenue by date.MEDS revenue by date.
9.89M
-42.23%		11.45M
15.77%		8.272M
-27.75%		9.486M
14.67%
EBITDA
YoY % growth
MEDS ebitda by date.MEDS ebitda by date.
-4.05M
-128.81%		-2.74M
32.35%		-6.429M
-134.64%		-663K
89.69%
EBIT
YoY % growth
MEDS ebit by date.MEDS ebit by date.
-4.06M
-128.09%		-2.75M
32.27%		-7.263M
-164.12%		-887.4K
87.78%
Operating Margin
MEDS operating margin by date.MEDS operating margin by date.
-41.05%-24.02%-87.80%-9.35%
EPS
YoY % growth
MEDS eps by date.MEDS eps by date.
-1.91
-730.43%		-4.80
-151.31%		N/A
77.69%		-0.46
57.14%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.150.00
100.00%
Revenue
Q2Q % growth		2.525M
22.69%		2.591M
10.14%
EBITDA
Q2Q % growth		-137.7K
73.04%		-40.8K
99.24%
EBIT
Q2Q % growth		-193.8K
77.07%		-96.9K
98.44%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

MEDS Yearly Revenue VS EstimatesMEDS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
MEDS Yearly EPS VS EstimatesMEDS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2020 2021 2022 2023 2024 0 -2 -4 -6 -8 -10

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

TRXADE HEALTH INC / MEDS Forecast FAQ

What do analysts expect the price target to be for TRXADE HEALTH INC (MEDS)?

7 analysts have analysed MEDS and the average price target is 6.89 USD. This implies a price decrease of -9.29% is expected in the next year compared to the current price of 7.59.

What are the consensus estimates for MEDS stock next earnings?

The consensus EPS estimate for the next earnings of TRXADE HEALTH INC (MEDS) is -0.15 USD and the consensus revenue estimate is 2.52M USD.

Can you provide the consensus rating for TRXADE HEALTH INC stock?

The consensus rating for TRXADE HEALTH INC (MEDS) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.